Literature DB >> 28291772

Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''.

Takeo Fujii1,2, Naoto T Ueno1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28291772      PMCID: PMC5396116          DOI: 10.1038/bjc.2017.61

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Sir, We thank K Altundag for the interest in our article (Fujii ) and thoughtful comments. Kurozumi reported that Ki67 level and histological grade were significantly associated with pathological complete response (pCR) after neoadjuvant chemotherapy with trastuzumab in patients with HER2-positive breast cancer. Polley reported that interlaboratory reproducibility of Ki67 was moderate. Although central staining demonstrated a better intraclass correlation coefficient: 0.71 (95% confidence interval, 0.47–0.78), in the setting of local staining, the intraclass correlation coefficient was low: 0.59 (95% confidence interval, 0.37–0.68). Also, the Ki67 value in patients who undergo neoadjuvant chemotherapy without endocrine therapy is still not obvious (Dowsett ), and the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (https://www.nccn.org/professionals/physician_gls/f_guidelines.asp) do not recommend testing Ki67 routinely. Because of its low reproducibility and lack of recommendation as a standard of care, Ki67 staining is not routinely performed as standard practice. Therefore, we excluded Ki67 from our analysis to make our nomogram practical. For histological grade, the hazard ratio was not significantly associated with pCR in multivariate analysis, despite the histological grade being a significant variable in univariate analysis in the study by Kurozumi . Therefore, we assume that the effect of not including nuclear or histological grade in our analysis was minimal. On the basis of these previous publications, many patients in our data set did not have Ki67 and histological grade. We agree with you that we cannot conclude anything about the clinical importance of Ki67 and histological grade in the context of neoadjuvant chemotherapy in patients with HER2-positive primary breast cancer unless we assess them in our model because this is a retrospective study. In conclusion, the effect of not including Ki67 and histological grade in our analysis is small, but we cannot make a definite conclusion unless we perform the same analysis including Ki67 and histological grade.
  4 in total

1.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

Authors:  Mitch Dowsett; Torsten O Nielsen; Roger A'Hern; John Bartlett; R Charles Coombes; Jack Cuzick; Matthew Ellis; N Lynn Henry; Judith C Hugh; Tracy Lively; Lisa McShane; Soon Paik; Frederique Penault-Llorca; Ljudmila Prudkin; Meredith Regan; Janine Salter; Christos Sotiriou; Ian E Smith; Giuseppe Viale; Jo Anne Zujewski; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2011-09-29       Impact factor: 13.506

2.  An international Ki67 reproducibility study.

Authors:  Mei-Yin C Polley; Samuel C Y Leung; Lisa M McShane; Dongxia Gao; Judith C Hugh; Mauro G Mastropasqua; Giuseppe Viale; Lila A Zabaglo; Frédérique Penault-Llorca; John M S Bartlett; Allen M Gown; W Fraser Symmans; Tammy Piper; Erika Mehl; Rebecca A Enos; Daniel F Hayes; Mitch Dowsett; Torsten O Nielsen
Journal:  J Natl Cancer Inst       Date:  2013-11-07       Impact factor: 13.506

3.  Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.

Authors:  Takeo Fujii; Takahiro Kogawa; Jimin Wu; Aysegul A Sahin; Dian D Liu; Mariana Chavez-MacGregor; Sharon H Giordano; Akshara Raghavendra; Rushmy K Murthy; Debu Tripathy; Yu Shen; Jose-Miguel Yamal; Naoto T Ueno
Journal:  Br J Cancer       Date:  2017-01-12       Impact factor: 7.640

4.  ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab.

Authors:  Sasagu Kurozumi; Kenichi Inoue; Hiroyuki Takei; Hiroshi Matsumoto; Masafumi Kurosumi; Jun Horiguchi; Izumi Takeyoshi; Tetsunari Oyama
Journal:  BMC Cancer       Date:  2015-09-07       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.